Tenofovir Disoproxil Fumarate, Efavirenz & Lamivudine Tablets

Indications & Clinical Uses

Tenofovir Disoproxil Fumarate, Efavirenz & Lamivudine Tablets are clinically indicated for:

• Treatment of HIV-1 Infection: Indicated as a complete standalone once-daily regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.
• First-Line Antiretroviral Therapy: Widely endorsed as an optimal initial treatment backbone to reduce viral load, restore CD4+ cell count, and delay disease progression.
• Management of Co-Infections: Both Tenofovir and Lamivudine exhibit dual inhibitory activity against Hepatitis B Virus (HBV), providing vital clinical utility in HIV-1 and HBV co-infected patients.

Mechanism of Action (How It Works)

This triple-drug fixed-dose formulation delivers a multi-targeted pharmacological attack against viral replication:

• Tenofovir Disoproxil Fumarate (Nucleotide RTI): An acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Once intracellularly metabolized into tenofovir diphosphate, it competitively inhibits HIV-1 reverse transcriptase and incorporates into viral DNA, causing immediate DNA chain termination.
• Lamivudine (Nucleoside RTI): A synthetic nucleoside analog of cytidine. Phosphorylated into lamivudine triphosphate, it acts as a competitive substrate for reverse transcriptase and terminates DNA synthesis, preventing viral genomic propagation.
• Efavirenz (Non-Nucleoside RTI): Binds directly to the allosteric non-nucleoside reverse transcriptase binding pocket, causing a conformational change that inactivates the catalytic site of HIV-1 reverse transcriptase without competing with natural deoxynucleotide triphosphates.

Key Therapeutic Benefits

• Potent Viral Suppression: Delivers rapid, deep, and durable reductions in plasma HIV-1 RNA levels.
• Immune Restoration: Promotes consistent increases in CD4+ T-cell counts, significantly reducing the incidence of opportunistic infections.
• Single-Tablet Convenience: Combining three active ingredients into a single once-daily tablet drastically enhances patient adherence and reduces pill burden.
• High Genetic Barrier: The complementary resistance profiles of tenofovir and efavirenz mitigate the development of therapeutic drug resistance.

Side Effects & Adverse Reactions

While generally well tolerated, patients receiving this combination therapy may experience adverse reactions that require clinical monitoring:

Common Adverse Effects:

• Central nervous system effects (dizziness, vivid dreams, insomnia, somnolence, difficulty concentrating – primarily related to Efavirenz, typically resolving within 2 to 4 weeks)
• Gastrointestinal disturbances (mild nausea, diarrhea, abdominal discomfort, flatulence)
• Skin rash (mild to moderate maculopapular rash, usually self-limiting)
• Fatigue, headache, and mild musculoskeletal aches

Serious Adverse Effects (Requiring Immediate Clinical Intervention):

• Lactic Acidosis & Severe Hepatomegaly with Steatosis: Potentially life-threatening metabolic complications linked to NRTI-induced mitochondrial toxicity.
• Renal Impairment: Acute renal failure, elevated serum creatinine, hypophosphatemia, and Fanconi syndrome associated with Tenofovir DF.
• Bone Mineral Density Loss: Osteopenia and accelerated bone demineralization leading to increased fracture vulnerability.
• Severe Neuropsychiatric Reactions: Severe depression, suicidal ideation, psychosis, and aggressive behavior associated with Efavirenz.
• Immune Reconstitution Inflammatory Syndrome (IRIS): Exaggerated inflammatory reactions against latent opportunistic pathogens during early therapy initiation.
• Severe Cutaneous Reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Clinical Precautions & Special Populations

• Bedtime Administration: Taking this medication at bedtime on an empty stomach is strongly recommended to minimize central nervous system adverse effects associated with Efavirenz.
• Renal Monitoring: Baseline and periodic assessment of estimated creatinine clearance (CrCl), serum phosphorus, urine glucose, and urine protein is essential.
• Hepatitis B Co-Infection: Patients must be screened for Hepatitis B virus prior to initiation. Abrupt discontinuation can provoke severe acute exacerbations of hepatitis.
• Pregnancy & Contraception: Women of childbearing potential should undergo pregnancy testing before starting therapy. Reliable barrier contraception must be utilized alongside hormonal contraceptives.
• Bone Health: Assessment of bone mineral density (BMD) is advised in individuals with a history of pathologic bone fractures or established osteoporosis risk factors.

Important Clinical Monitoring Parameters

• Plasma HIV-1 RNA (viral load) and CD4+ T-cell count at baseline and at regular therapeutic intervals
• Renal function parameters: Serum creatinine, estimated GFR, serum phosphorus, and urinalysis
• Hepatic transaminases (ALT, AST) and total bilirubin, especially in patients with viral hepatitis co-infection
• Fasting lipid panel and blood glucose levels due to potential Efavirenz-associated metabolic alterations
• Mental status and psychiatric screening for mood or affective disorders

Contraindications & Warnings

• Hypersensitivity: Strictly contraindicated in individuals with known hypersensitivity to Tenofovir Disoproxil Fumarate, Efavirenz, Lamivudine, or any formulation excipients.
• Hepatic Impairment: Contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).
• Co-Administration Warnings: Must not be co-administered with other antiretrovirals containing tenofovir, lamivudine, emtricitabine, efavirenz, or adefovir dipivoxil.
• Drug-Induced QT Prolongation: Avoid concomitant use with medications known to prolong the QTc interval or in patients with congenital long QT syndrome.

Drug Interactions

• Nephrotoxic Agents: Avoid concurrent use with drugs that reduce renal function or compete for active tubular secretion (e.g., high-dose NSAIDs, aminoglycosides, amphotericin B, cidofovir, vancomycin).
• CYP3A4 Inducers & Inhibitors: Efavirenz is a substrate and inducer of CYP3A4. Concomitant administration with St. John’s Wort, carbamazepine, phenobarbital, and rifampin significantly reduces plasma concentrations and must be avoided.
• Anticoagulants & Anticonvulsants: Plasma levels of warfarin, phenytoin, and carbamazepine may be altered, requiring therapeutic drug monitoring.
• Oral Contraceptives: Efavirenz interacts with ethinyl estradiol; non-hormonal and barrier methods of birth control are mandatory.

Storage & Handling Information

Store Tenofovir Disoproxil Fumarate, Efavirenz & Lamivudine Tablets in their original tightly closed container at controlled room temperature between 20°C and 25°C (68°F to 77°F). Protect from excessive moisture, direct sunlight, and heat. Keep securely out of reach of children and pets.